Our second Modulating the Tumour Microenvironment conference presents innovations for enhancing the immune anti-tumour response and overcoming inhibitory factors. It is becoming clear that many immunosuppressive mechanisms are at work. The checkpoint inhibitors are not living up to expectations, and for these and other antagonists to be effective, it is necessary to control Tregs and manipulate myeloid-derived and other suppressor cells in the tumour microenvironment (TME). The leaders in the field are also paying attention to the role of cytokines and the importance of Fc-engagement for effective targeting.

Preliminary Agenda

THE KEY TO THERAPEUTIC SUCCESS

Using Antibodies to Target the Tumour Microenvironment - Good Intentions Can Often Lead to Unintended Consequences.

Stephen Beers, PhD, Professor, Immunology and Immunotherapy, Centre for Cancer Immunology, Cancer Sciences Unit, University of Southampton

Fc-Dependent Expansion of Distinct Memory Populations Defines the Antitumor Efficacy of Checkpoint Immunotherapy

Jeremy Waight, PhD, Principal Scientist, Immunomodulatory Drug Discovery, Agenus

DEVELOPMENTS WITH IMMUNOCYTOKINES

Development of Novel Immunocytokines for Cancer Immunotherapy

Christian Klein, PhD, Head, Oncology Programs, Head, Cancer Immunotherapy Discovery, Roche Pharmaceutical Research and Early Development (pRED) Roche Innovation Center Zurich

Novel Formats for Antibody-Cytokine Fusion Proteins: Impact on Performance

Dario Neri, PhD, Professor, Chemistry and Applied Biosciences, Swiss Federal Institute of Technology (ETH Zürich)

Targeted Cytokine Sweeping Activity Using New Bispecific Formats

Marie-Alix Poul, PhD, Professor, Immunology, Biology-Life Science, University of Montpelier, IRCM

TARGETING IMMUNE CHECKPOINTS

Targeting Antibody Checkpoints – Focus on FcγRIIB

Björn Frendéus, PhD, CSO, BioInvent International AB

The Development of KY1043 - A Highly Differentiated PD-L1-Based IL-2Ra Biased Immunocytokine

Matthew McCourt, PhD, VP, Immuno-Oncology, Kymab Ltd.

TARGETING MACROPHAGES AND THE INNATE IMMUNE SYSTEM TO ENHANCE IMMUNOTHERAPY

Targeting Tumor Associated Macrophages to Improve Cancer Immunotherapy

Minhong Yan, PhD, Principal Scientist, Molecular Oncology Genentech, Inc.

Selectively Inhibiting CD47 in the Tumor Microenvironment

Nicolas Fischer, PhD, Head, R&D, Novimmune

TLR Agonist NKTR-262 Immunotherapy Combination with Bempegaldesleukin (NKTR-214) Harnessing Innate and Adaptive Immune System for the Treatment of Solid Tumors

Saul Kivimäe, PhD, Head, in vivo Pharmacology Function, Research Biology, Nektar Therapeutics

FOCUS ON CANCER-SPECIFIC GLYCOFORMS AND GLYCO-IMMUNE CHECKPOINTS

Aberrant Glycosylation in Breast Cancer Results in Modulation of the Immune Microenvironment

Joy Burchell, PhD, Professor, Glyco-oncology, Head, Breast Cancer Biology Lab, Comprehensive Cancer Centre, School of Cancer and Pharmaceutical Sciences, King’s College London

Targeting Immunosuppressive Sialoglycans in the Tumor Microenvironment Using a Novel Therapeutic Modality EAGLE

Li Peng, PhD, SVP, Discovery and Early Product Development, Palleon Pharmaceuticals



* The program is subject to change without notice, due to unforeseen reason.

Choose your language
Japanese
Traditional Chinese
Simplified Chinese
Korean